• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications do not work for many people who are depressed. Personalized treatment could be the solution.

Cue is an intervention platform for digital devices that translates passively acquired normal smartphone sensor data into personalized micro-interventions that improve mental health. We looked at the best-fitting personal ML models to each person, using Shapley values to discover their features and predictors. This revealed distinct features that deterministically changed mood over time.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet the majority of people affected receive treatment. To improve the outcomes, doctors must be able to identify and treat patients who are most likely to respond to certain treatments.

The treatment of depression can be personalized to help. By using sensors on mobile phones as well as an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. Two grants worth more than $10 million will be used to discover the biological and behavioral indicators of response.

The majority of research to the present has been focused on clinical and sociodemographic characteristics. These include demographics such as age, gender and education as well as clinical aspects such as symptom severity and comorbidities, as well as biological markers.

While many of these variables can be predicted from data in medical records, only a few studies have utilized longitudinal data to determine predictors of mood in individuals. Many studies do not take into consideration the fact that mood can vary significantly between individuals. Therefore, it is essential to create methods that allow the recognition of the individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can systematically identify distinct patterns of behavior and emotion that vary between individuals.

The team also devised an algorithm for machine learning to model dynamic predictors for each person's depression mood. The algorithm blends these individual variations into a distinct "digital phenotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, which is a psychometrically validated severity scale for symptom severity. However the correlation was not strong (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely across individuals.

Predictors of symptoms

Depression is one of the leading causes of disability1, but it is often underdiagnosed and undertreated2. Depression disorders are rarely treated due to the stigma that surrounds them and the absence of effective interventions.

To allow for individualized treatment, identifying patterns that can predict symptoms is essential. However, current prediction methods depend on the clinical interview which is unreliable and only detects a tiny number of features associated with depression.2

Using machine learning to integrate continuous digital behavioral phenotypes that are captured by sensors on smartphones and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory, CAT-DI) along with other indicators of symptom severity could improve diagnostic accuracy and increase treatment efficacy for depression. Digital phenotypes are able to are able to capture a variety of unique behaviors and activities, which are difficult to document through interviews, and also allow for high-resolution, continuous measurements.

The study comprised University of California Los Angeles students with moderate to severe depression symptoms who were taking part in the Screening and Treatment for anxiety depression treatment and residential depression treatment uk program29 developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical care according to the severity of their depression. Those with a score on the CAT-DI scale of 35 or 65 students were assigned online support by an instructor and those with a score 75 were routed to clinics in-person for psychotherapy.

At baseline, participants provided the answers to a series of questions concerning their personal demographics and psychosocial features. The questions included age, sex and education and financial status, marital status as well as whether they divorced or not, their current suicidal thoughts, intent or attempts, and the frequency with which they consumed alcohol. The CAT-DI was used to rate the severity of depression symptoms on a scale ranging from zero to 100. The CAT DI assessment was conducted every two weeks for participants who received online support and weekly for those who received in-person care.

Predictors of Treatment Response

The development of a personalized depression treatment is currently a research priority and a lot of studies are aimed to identify predictors that enable clinicians to determine the most effective drugs for each individual. Pharmacogenetics, in particular, is a method of identifying genetic variations that affect how the body's metabolism reacts to drugs. This allows doctors select medications that are likely to be the most effective for each patient, reducing the time and effort needed for trial-and error treatments and avoiding any side consequences.

Another promising approach is to build predictive models that incorporate clinical data and neural imaging data. These models can be used to identify the best combination of variables that is predictors of a specific outcome, such as whether or not a medication will improve the mood and symptoms. These models can also be used to predict the response of a patient to a treatment they are currently receiving which allows doctors to maximize the effectiveness of current treatment.

A new era of research uses machine learning methods like supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to combine the effects of many variables and improve the accuracy of predictive. These models have been proven to be effective in the prediction of treatment outcomes like the response to antidepressants. These methods are becoming popular in psychiatry and it is expected that they will become the standard for future clinical practice.

In addition to prediction models based on ML, research into the mechanisms that cause depression continues. Recent findings suggest that the disorder is associated with dysfunctions in specific neural circuits. This suggests that individual depression treatment will be based on targeted therapies that target these circuits in order to restore normal functioning.

One method to achieve this is to use internet-based interventions which can offer an personalized and customized experience for patients. A study showed that a web-based program improved symptoms and led to a better quality life for MDD patients. In addition, a controlled randomized study of a personalised approach to depression treatment showed an improvement in symptoms and fewer side effects in a significant number of participants.

Predictors of Side Effects

In the treatment of depression, one of the most difficult aspects is predicting and identifying the antidepressant that will cause very little or no negative side negative effects. Many patients are prescribed a variety of medications before finding a medication that is both effective and well-tolerated. Pharmacogenetics provides a novel and exciting way to select antidepressant medications that is more effective and precise.

There are many predictors that can be used to determine the antidepressant to be prescribed, including genetic variations, phenotypes of the patient such as gender or ethnicity, and comorbidities. However it is difficult to determine the most reliable and reliable predictive factors for a specific treatment is likely to require randomized controlled trials with significantly larger numbers of participants than those that are typically part of clinical trials. This is because the detection of moderators or interaction effects may be much more difficult in trials that only focus on a single instance of magnetic treatment for depression per patient, rather than multiple episodes of treatment over time.

Furthermore, predicting a patient's response will likely require information about the severity of symptoms, comorbidities and the patient's subjective perception of the effectiveness and tolerability. Currently, only some easily assessable sociodemographic and clinical variables are believed to be reliably associated with the response to MDD factors, including age, gender race/ethnicity BMI and the presence of alexithymia, and the severity of depressive symptoms.

Many issues remain to be resolved in the application of pharmacogenetics in the treatment resistant depression treatment of depression. First it is necessary to have a clear understanding of the underlying genetic mechanisms is essential as well as a clear definition of what is a reliable predictor of treatment response. Additionally, ethical issues like privacy and the appropriate use of personal genetic information must be considered carefully. In the long-term pharmacogenetics can be a way to lessen the stigma associated with mental health treatment and improve treatment outcomes for those struggling with depression. Like any other psychiatric treatment it is crucial to take your time and carefully implement the plan. For now, it is best to offer patients various depression treatment in pregnancy medications that work and encourage patients to openly talk with their doctor.